- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01133639
Ketorolac Effects on Post-operative Pain and Bone Healing
August 20, 2019 updated by: Emily Cook, Beth Israel Deaconess Medical Center
Does Ketorolac Delay Bone Healing and Improve Post-operative Pain?: A Prospective Double-Blind Placebo-Controlled Randomized Clinical Trial
This will be a randomized double-blind placebo-controlled clinical trial that will accept all eligible consecutive patients undergoing elective Kalish bunionectomies.
Patients will be randomized into either receiving ketorolac (30 mg IV dose intra-operatively followed by 10 mg orally every 8 hours for five days) plus standard of care or placebo plus standard of care.
The purpose of this study is to evaluate the effects of ketorolac plus standard of care on post-operative pain control and radiographic osseous healing.
Patients will be assessed for pain via a validated pain questionnaire and for delayed unions via a radiographic scoring system shown to have both high inter- and intra-observer reliability by a blinded board certified radiologist.
Additional outcomes of bunionectomy procedures will also be evaluated including adverse events and time to regular shoe gear and activities.
Study Overview
Study Type
Interventional
Enrollment (Actual)
18
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Hallux abductus with bunion deformity
- Adult patients as defined by >=18 years old and <= 65 years old
- Subject has adequate perfusion, verified by the surgeon, which is defined by palpable pedal pulses
- Subject has voluntarily signed and dated an informed consent form, approved by IRB, and provided HIPAA (or other applicable privacy regulation) authorization prior to any participation in the study
- Subject agrees not to take any new medications, dietary supplements, or alternative therapies during the study period (approximately 12 weeks)
- Subject is interested in participating in the study and willing to comply with the study protocol
- Patient has pain related to a bunion deformity but pain-free metatarsalphalangeal joint (MTPJ) range of motion that is not functionally adapted
- Adequate bone density to withstand a Kalish bunionectomy procedure
- No frontal plane hallux deformity
- Minimal abnormality of the PASA
- Normal to minimally malaligned sagittal plane position of the first metatarsal
- Failure of conservative treatment
- General Pre-operative Radiographic Angle Criteria† - 10-15 degree IMA in rectus feet* - 20-25 degree TAA in adducted feet* - 15-20 degree IMA in rectus feet if wide metatarsal head width - 25-30 degree TAA in adducted feet if wide metatarsal head width IMA=intermetatarsal angle; TAA=total adductus angle *If the pre-operative IMA is <15 degree, only the IMA will be used pre-operatively. For IMA >=15, the total adductus angle will be used †These are general guidelines and the width of the metatarsal as well as the presence of positional, structural, or combined first ray deformity may also influence procedure selection.
Exclusion Criteria:
- a history of an allergic-type reaction in response to exposure to aspirin, phenylacetic acid derivatives, or other NSAIDs
- hypersensitivity to ketorolac tromethamine, or to any product component
- any known bleeding risk or bleeding disorder, suspected or confirmed
- history of or active cerebrovascular bleeding, suspected or confirmed
- concomitant aspirin or NSAID use where the patient may not be advised to discontinue the medication during the study
- concomitant pentoxifylline use
- concomitant probenecid use
- coronary artery bypass graft (CABG) surgery within one year of the procedure
- any history of gastrointestinal bleeding/perforation, gastrointestinal ulcer, severe peptic ulcer disease, or severe inflammatory bowel disease
- hemorrhagic diathesis, suspected or confirmed
- incomplete intraoperative hemostasis
- pre-operative serum creatinine > 1.5 ml/dL or blood urea nitrogen level > 22 mg/dL
any history of renal impairment or risk of renal failure due to volume depletion
- Patients with a known allergy, contraindication and/or intolerance for oxycodone 5mg - acetaminophen 325 mg will be excluded from the study.
- Patients with a known allergy, contraindication, and/or intolerance for the local anesthetic (bupivicaine) or any of the standardized intra-operative opioids and anti-emetics administered by the anesthesiologist
- Patients with a history of fibromyalgia or opioid abuse
- History of chronic regional pain syndrome or diagnosis of any chronic pain syndrome, patients requiring routine methadone or other opioids
- Neuropathy or radiculopathy
- Subject has alcohol or substance abuse, dementia, brain metastases, or other cognitive disorders that may interfere with pain assessment and the post-operative course outlined by the surgeon
- American Society of Anesthesiologists (ASA) Physical Status class four or higher
- women who are pregnant, planning on becoming pregnant, or breast feeding
- presence of active local or systemic infection
subject has a myocardial infarction in the last twelve months
• Patients who are not candidates for a Kalish bunionectomy due to the preoperative deformity as well as other study exclusions are:
- Absent pedal pulses or ABI < 0.9 and > 1.2
- Concomitant midfoot and rearfoot procedures
- Moderate to high abnormal PASA angles
- Significant sagittal plane first metatarsal deformity
- Moderate to severe osteoporosis as evaluated by preoperative radiographs and/or bone mineral density tests
- Revision cases
- History of previous infections, radiation treatment, or current infection related to the surgical site
- History of previous trauma of the first metatarsal or first ray
- Subject has known immunosuppression (HIV, recent chemotherapy, organ transplant)
- Patients taking systemic steroid (patients taking less than 5 mg of prednisone, inhaled steroids for asthma or chronic obstructive pulmonary disease, topical or optical steroids will not be excluded)
- Subject has active malignancy, excluding cutaneous malignancies except melanoma Pregnancy Elective bunion surgery will not be performed if the patient is pregnant or planning on becoming pregnant during this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Placebo plus standard of care
|
Placebo plus standard of care
|
Experimental: Ketorolac
30 mg IV dose intra-operatively followed by 10 mg orally every 8 hours for five days plus standard of care
|
30 mg IV dose intra-operatively followed by 10 mg orally every 8 hours for five days plus standard of care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Post-Operative Pain
Time Frame: Post-Operative Day 2
|
18 subjects were enrolled & completed the study.
Pharmacy held the randomization table.
PI left institution & was never unblinded (because there were never any AEs).
Therefore, do not know which subjects were in the placebo vs ketorolac arms.
Study was terminated due to lack of administrative support 2/2012 & all data has been destroyed.
|
Post-Operative Day 2
|
Osseous Healing
Time Frame: 3 months
|
Radiographic assessment by a blinded board certified radiologist
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Post-operative Activity Recovery
Time Frame: up to 3 months
|
Functional Recovery Index
|
up to 3 months
|
Adverse Events
Time Frame: 1 week
|
Comparison of adverse events between the two study arms
|
1 week
|
Quantity of Narcotic Medication
Time Frame: 1 week
|
Comparison of quantity of narcotic medication utilized within the two study arms
|
1 week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Emily A Cook, DPM, MPH, Beth Israel Deaconess Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2010
Primary Completion (Actual)
February 1, 2012
Study Completion (Actual)
February 1, 2012
Study Registration Dates
First Submitted
May 27, 2010
First Submitted That Met QC Criteria
May 27, 2010
First Posted (Estimate)
May 31, 2010
Study Record Updates
Last Update Posted (Actual)
August 21, 2019
Last Update Submitted That Met QC Criteria
August 20, 2019
Last Verified
August 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Postoperative Complications
- Pain
- Neurologic Manifestations
- Pain, Postoperative
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Ketorolac
Other Study ID Numbers
- 2010P000047
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bunion
-
Chinese University of Hong KongCompletedHallux Valgus | Hallux Valgus and BunionHong Kong
-
Hospital Mutua de TerrassaUnknownHallux Valgus and Bunion (Disorder)Spain
-
Assiut UniversityNot yet recruitingHallux Valgus and Bunion
-
China Medical University HospitalUnknownHallux Valgus and Bunion (Disorder)Taiwan
-
North District HospitalChinese University of Hong KongCompleted
-
Pacira Pharmaceuticals, IncCompleted
-
Istituto Ortopedico RizzoliRecruiting
-
Ostfold Hospital TrustNot yet recruiting
-
Istanbul Medipol University HospitalCompleted
-
Istituto Ortopedico RizzoliCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States